Objective: Lipodystrophy is the major complication of antiretroviral therapy in HIV-infected patients. Its pathophysiology is not well understood, but has been linked to antiadipogenic effects of antiretroviral drugs. Lipin represents a newly characterized protein that is critical for adipocyte differentiation, and lipin deficiency leads to lipodystrophy in the mouse. The objective of this study was to determine whether altered lipin gene expression is associated with HIV lipodystrophy in humans. Design: We measured lipin mRNA levels in subcutaneous abdominal and femoral-gluteal adipose tissue biopsies from HIVinfected patients with or without lipodystrophy, and in healthy controls. Real-time reverse transcription-PCR was performed to quantitate total lipin expression levels, and expression of two lipin isoforms (lipin-a and -b) that are generated by alternative mRNA splicing. Results: As predicted from studies with mice, lipin mRNA levels were correlated with limb fat mass in HIV patients, with lower lipin levels in patients with lipodystrophy than those without lipodystrophy. Unexpectedly, however, this was explained by an increase in lipin-b expression in HIV patients without lipodystrophy compared to patients with lipodystrophy and control subjects. In addition, lipin expression levels were inversely correlated with adipose tissue expression of inflammatory cytokines interleukin (IL)-6, IL-8 and IL-18, which typically increase in HIV-associated lipoatrophy. Conclusions: Elevated lipin expression levels are associated both with the maintenance of greater fat mass and lower cytokine expression in HIV-infected patients. Based on the demonstrated role for lipin in promoting lipogenic gene expression, these observations raise the possibility that variations in lipin levels may contribute to variations in adipose tissue mass and function that distinguish HIV patients with and without lipodystrophy.
Introduction
Lipodystrophy (peripheral lipoatrophy, central fat accumulation and lipomatosis) is a common and disfiguring problem in adult patients with HIV-1 infection undergoing antiretroviral therapy. 1 Lipodystrophy in these patients is characterized by the loss of subcutaneous fat in the peripheral adipose tissue depots of the arms, legs and face and central adipose tissue, with or without concomitant fat deposition in neck and intra-abdominal regions. [2] [3] [4] As with congenital forms of lipodystrophy, antiviral therapy-induced lipodystrophy is often associated with insulin resistance. [4] [5] [6] [7] Antiretroviral therapy typically involves treatment with a combination of drugs including nucleoside analogs and protease inhibitors. These compounds appear to influence the differentiation, lipid storage and function of adipocytes. [8] [9] [10] [11] [12] [13] [14] For example, the nucleoside analogs stavudine and zidovudine have a marked influence on the lipid phenotype of cultured adipocytes, decreasing the lipid content and expression of markers involved in adipocyte differentiation and lipid metabolism, such as CAAT-enhancer binding protein (C/EBP)a, peroxisome proliferator-activated receptor (PPAR)g, adipocyte lipid binding protein 2, fatty acid synthase and acetyl-coenzyme A carboxylase. 14 The protease inhibitors indinavir and nelfinavir also alter adipocyte differentiation, affecting the expression levels of sterol regulatory element binding protein-1, C/EBPa and fatty acid synthase. 13 Thus, the use of a combination of antiretroviral drugs may impair both adipocyte differentiation and function of mature adipocytes.
The fatty liver dystrophy (fld) mouse resembles human patients with generalized lipodystrophy, having dramatically reduced adipose tissue stores throughout the body, insulin resistance and increased susceptibility to atherosclerosis. 15, 16 Recently, we identified the causative mutation in the Lpin1 gene, which encodes a novel protein, lipin. 17 Lipin is expressed prominently in adipose tissue and skeletal muscle, and at lower levels in tissues such as liver. Studies in lipindeficient and lipin transgenic mouse models have demonstrated that lipin has a profound effect on adiposity and adipocyte gene expression. 18 Lipodystrophy in lipindeficient mice can be attributed to an absolute requirement for lipin in adipocyte differentiation. In the absence of lipin, adipocytes fail to induce key adipogenic genes including PPARg and C/EBPa, and do not accumulate lipid or express genes characteristic of mature adipocytes. 19 In contrast, transgenic mice with enhanced lipin expression in adipose tissue exhibit increased expression of lipogenic genes, increased lipid storage per adipocyte and accelerated dietinduced obesity. 18 Thus, lipin has critical roles in both adipocyte differentiation and in the maintenance of mature adipocyte function and lipogenesis. The cellular function of mammalian lipin is not yet known. Very recent work in yeast demonstrated that the Saccharomyces cerevisiae homolog of lipin, Smp2, has phosphatidic acid phosphatase (PAP-1) activity. 20 PAP-1 is a key enzyme in the triacylglycerol biosynthetic pathway, responsible for the conversion of phosphatidic acid phosphate to diacylglycerol. However, it is not yet known whether lipin is responsible for the corresponding activity in mammalian tissues. Furthermore, the situation is more complex in mammalian cells, which express two lipin isoforms, a and b, derived from alternative mRNA splicing of the Lpin1 gene. 21, 22 Studies in cultured cells and transgenic mouse models suggest that the two isoforms have distinct roles in adipocyte differentiation and maturation. Both lipin isoforms are expressed in preadipocytes and in mature adipocytes, but lipin-a is the predominant form in preadipocytes and early stages of differentiation, whereas lipin-b predominates in mature adipocytes. 22 The two lipin isoforms also differ functionally: the lipin-a isoform promotes expression of adipogenic transcription factors including PPARg and C/EBPa, whereas the lipin-b isoform enhances expression of genes involved in lipogenesis and lipid storage in mature adipocytes. 22 Thus, it appears that in addition to the levels of total lipin expression, the relative levels of lipin-a and -b isoforms may be important factors in adipocyte differentiation and lipogenesis. The demonstration that lipin plays a key role in adipocyte differentiation and mature adipocyte function raises the question of whether altered lipin levels may be a factor in human disorders characterized by lipodystrophy. We therefore hypothesized that lipin expression may be reduced in human adipose tissue from HIV patients with lipodystrophy compared to those without lipodystrophy. Here we report a direct correlation between lipin expression levels and percentage limb fat in HIV patients, and an inverse correlation between lipin levels and inflammatory cytokine expression in adipose tissue. These results implicate lipin expression levels as a potential determinant or marker of lipodystrophy severity in HIV patients undergoing antiretroviral therapy.
Materials and methods

Subjects
Thirty-four HIV-positive men were recruited from the outpatient clinic of the Department of Infectious Disease, Rigshospitalet, Copenhagen, Denmark. Lipodystrophy was defined clinically by physical examination of peripheral lipoatrophy (fat loss from face, arms, buttocks or legs). 23 Agematched patients were enrolled into the following two groups according to clinical examination: patients with lipodystrophy (LD þ , n ¼ 17) and patients without lipodystrophy (LDÀ, n ¼ 17). All patients were on a stable and effective nucleoside analog-based HAART with no changes in antiretroviral therapy during the preceding 8 weeks. All patients were receiving nucleoside reverse transcriptase inhibitors. In the LD þ group, 12 patients were receiving protease inhibitors and nine non-nucleoside analogs. In the LDÀ group, nine patients were receiving protease inhibitors and three non-nucleoside analogs. Twenty-two age-matched HIV-seronegative healthy men without the metabolic syndrome (the WHO definition: body mass index (BMI)427 kg/m 2 , total cholesterol46.2 mmol/l, triglycerides41.7 mmol/l, highdensity lipoprotein (HDL)-cholesterol o0.9 mmol/l) served as controls. Demographic data were collected for each patient: age, weight, height, duration of HIV infection, duration and types of all antiretroviral therapy, CD4 cell count and HIV-RNA copies. The patients had no signs of ongoing infections and had fasting glucose below 7 mmol/l. Informed consent was obtained from all patients according to the requirements of the local ethics committee.
Body composition analysis
Fat and fat-free tissue masses for the whole body, trunk and extremities were measured using a dual-energy X-ray absorptiometry scanner, Norland XR 36 (Norland Corporation, Fort Atkinson, WI, USA) software version 3.94. Patients were placed as previously described. 1 The scanner was calibrated daily against the standard calibration block supplied by the manufacturer. All measurements were performed in a single laboratory. Whole-body and regional fat measurements (trunk and extremity) were determined as previously described. 1, 24 Percentage of limb fat and truncal fat was calculated as the arm and leg fat mass or truncal fat mass, respectively, expressed as percentage of total fat mass. 24 Waist-to-hip ratio was measured as waist circumference at the level of umbilicus divided by hip circumference in the horizontal plane at the level of the maximal extensions of the buttocks.
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Blood samples
Blood samples were obtained after an overnight fast. Total cholesterol (mmol/l), HDL-cholesterol (mmol/l), low-density lipoprotein (LDL)-cholesterol (mmol/l), triglycerides (mmol/l) and plasma glucose (mmol/l) were determined using standard laboratory procedures. CD4 cell counts were calculated by flow cytometry and HIV-RNA copies were measured by the Amplicor Hiv Monitor (Roche Molecular Systems, Branchburg, NJ, USA) (lower limit of detection: 20 copies/ml). Insulin was measured in ethylenediaminetetraacetic acid-plasma by enzyme-linked immunosorbent assay (DakoCytomation Ltd, Cambridgeshire, UK). Detection limit was 3.0 pg/ml. All samples and standards were run as duplicates and the mean of duplicates was used in the statistical analyses. Plasma samples were stored at À801C until analyzed.
Tissue biopsies
Adipose tissue biopsies were obtained after an overnight fast. Subcutaneous adipose tissues were obtained by use of the percutaneous biopsy technique with suction from the subumbilical abdominal region and lateral femoral-gluteal region under local anesthesia with 2% lidocaine. Adipose tissue was immediately frozen in liquid nitrogen and stored at À801C until analyzed. Paired fat biopsies (femoral-gluteal as well as abdominal compartments) for measurement of lipin mRNA were obtained from seven out of 17 patients with LD, eight out of 17 patients without LD and 17 out of 22 controls. Data presented on femoral-gluteal fat are therefore selected. However, the lipin mRNA level in abdominal AT did not differ according to whether a paired femoro-gluteal fat biopsy was obtained or not.
Quantification of lipin mRNA expression
For validation of primer sets, total adipose tissue RNA was obtained from a commercial supplier (Ambion, Austin, TX, USA). For all other studies, total RNA was isolated from adipose tissue with TriZol (Life Technology, Gaithersburg, MD, USA), as described by the manufacturer. Two micrograms of RNA was reverse transcribed to cDNA with the use of random hexamers (Taqman reverse transcription reagents, Applied Biosystems, Foster City, CA, USA). Studies in Figure 1 were performed by standard PCR for 32 cycles using an annealing temperature of 551C in Failsafe Buffer H (Epicentre Biotechnologies, Madison, WI, USA), and products analyzed on 2% agarose gels. Real-time PCR was performed on an ABI PRISM 7900 sequence detector (PE Biosystems, Foster City CA, USA). Each assay included (in triplicate) a cDNA standard curve of five serial dilution points (ranging from 1 to 0.01), a no-template control, a no-reverse transcriptase control and 50 ng (10 ng for 18S rRNA) of each sample cDNA. For total lipin, lipin-a and lipin-b, an amplification reagent mixture of 35 ml was made up with 50 ng cDNA, 10 pmol forward primer, 10 pmol reverse primer and 1 Â Taqman SYBR green PCR master Mix. Samples were incubated in the Taqman for an initial denaturation at 951C for 11 min, followed by 50 PCR cycles, each consisting of 951C for 30 s, 551C for 30 s and 721C for 30 s. For 18S rRNA, tumor necrosis factor (TNF)-a, interleukin (IL)-18 and IL-6, the amplification mixtures were prepared with 1 Â Taqman Universal PCR master mix and amplified according to standard conditions using 50 cycles. All assay reagents were from Applied Biosystems. Primers and Taqman probes for 18S rRNA, TNFa and IL-18 were predeveloped assay reagents from Applied Biosystems. Primers and Taqman probes for human IL-6 were as previously described. 25 The relative concentrations of total lipin, lipin-a, lipin-b, TNF-a, IL-18, IL-6 and the endogenous control 18S rRNA were determined by plotting the threshold cycle (C t ) vs the log of the serial dilution points, and the relative expression of the gene of interest was determined after normalization to the endogenous control. Lipin PCR primers were as follows:
total lipin: hLPIN-f/hLPIN-r lipin-a:
hLPIN-f/hLPINa-r lipin-b:
hLPIN-f/hLPINb-r hLPIN-f: For total lipin, a forward primer (f) spanning the exon 5/6 junction was paired with a reverse primer (r) in exon 6, which is present in both splice forms of lipin mRNA. To detect lipina, the same forward primer was paired with reverse primer a-r, which spans the junction between exons 6 and 8 that occurs exclusively in mRNA produced from this splice form. To detect lipin-b, the same forward primer was paired with the reverse primer b-r, which is located in the alternative exon 7, present exclusively in this isoform. 
Results
Characteristics of HIV patients with and without lipodystrophy
The clinical characteristics of subjects studied are shown in Table 1 . There were no significant differences in the duration of the HIV infection, CD4 þ cell count and HIV-RNA copy number between HIV-infected patients with and without lipodystrophy. The subjects with clinical lipodystrophy (LD þ ) had received therapy for an average of 30.2 months longer than subjects without lipodystrophy (LDÀ), and had a lower BMI when compared to healthy controls. All subjects had comparable waist-to-hip ratio and total lean body mass. Patients classified as LD þ had a significant reduction in total fat mass, limb fat mass and percentage limb fat compared to both control subjects and HIV patients classified as LDÀ. Despite no significant differences in BMI or lean body mass compared to control subjects, the LDÀ patients did exhibit a modest reduction in limb fat mass. The LDÀ group may therefore represent an intermediate phenotype that does not fit a clinical classification of lipodystrophy, but which nevertheless exhibits some alterations compared to control subjects. Subjects in the three groups showed no differences in fasting plasma insulin or glucose levels. Total cholesterol and triglyceride levels were higher in patients with lipodystrophy, whereas there were no differences in HDL-cholesterol and LDL-cholesterol.
Elevated lipin mRNA levels in HIV patients without lipodystrophy We quantitated lipin mRNA levels via real-time reverse transcription-PCR (RT-PCR) using distinct PCR primer combinations to detect total lipin mRNA, or exclusively lipin-a or lipin-b isoform mRNA (see Figure 1 ). Lipin-a and -b mRNAs differ by exclusion (lipin-a) or inclusion (lipin-b) of exon 7 of Lipin in HIV lipodystrophy B Lindegaard et al the LPIN1 gene, as we have shown in the mouse. 22 Therefore, PCR primer sets using a common forward primer (f) but distinct reverse primers allow detection of either total lipin (reverse primer r), lipin-a (reverse primer a-r) or lipin-b (reverse primer b-r). Expression of both lipin isoforms was detected in human subcutaneous adipose tissue from both the abdominal and femoro-gluteal compartments. Lipin mRNA levels were determined in adipose tissue from each of the three groups -control subjects, HIV patients without lipodystrophy and HIV patients with lipodystrophy. HIV patients with lipodystrophy had lipin levels similar to control patients in both abdominal and femoro-gluteal depots. However, lipin expression levels in LD þ patients were reduced compared to LDÀ patients. This was true for total lipin in both the abdominal and femoro-gluteal compartments (P ¼ 0.045 and P ¼ 0.019, respectively; see Figure 2a ). Lipin-a mRNA was also reduced in LD þ patients in both adipose tissue compartments (abdominal region: P ¼ 0.045; femoro-gluteal region: P ¼ 0.014; see Figure 2b ), whereas the level of lipin-b mRNA was significantly lower only in the abdominal region (abdominal region: P ¼ 0.029; femoro-gluteal region: P ¼ 0.166; see Figure 2c ). Lipin levels in LDÀ patients tended to be elevated compared to control subjects and LD þ patients. This reached statistical significance for lipin-b mRNA levels in the abdominal subcutaneous fat depot compared to healthy controls (P ¼ 0.004) and LD þ patients (P ¼ 0.029; see Figure 2c ). Lipin-b levels were also elevated in the femoro-gluteal depot, but did not reach statistical significance owing to inter-individual variation (P ¼ 0.066). The elevated lipin levels in LDÀ patients cannot be attributed to higher fat mass, as these subjects have reduced fat mass compared to the control subjects (see Table 1 ). Thus, HIV patients who have not developed lipodystrophy exhibit higher expression of all lipin isoforms than lipodystrophic patients, and elevated lipin-b expression compared to control subjects.
The two subcutaneous adipose tissue depots examined here also showed a difference in lipin levels. A comparison of lipin levels in the abdominal vs femoro-gluteal samples from subjects for which paired samples were available (controls, n ¼ 17; LDÀ, n ¼ 8; LD þ , n ¼ 7) revealed lower lipin expression in the femero-gluteal subcutaneous depot (total lipin, P ¼ 0.003; lipin-a, P ¼ 0.023; and lipin-b, P ¼ 0.002). These differences were primarily owing to differences in patients with lipodystrophy, who exhibited lower lipin mRNA in the femero-gluteal compared to abdominal depots (total lipin, P ¼ 0.019; lipin-a, P ¼ 0.008; lipin-b, P ¼ 0.038). 
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Lipin levels correlate with percentage limb fat in HIV patients
Lipin levels in the adipose tissue of HIV patients showed a positive correlation with percentage limb fat. Thus, in the HIV group, a univariate regression analysis revealed that a 0.1 unit reduction in total lipin mRNA Log 10 (normalized as lipin mRNA/18S rRNA) in the femoro-gluteal or in the abdominal region resulted in a reduction in percentage limb fat of 1.8% (95% CI: 1.1-2.5; Po0.0001) and 2.5% (95% CI: 0.3-2.2; P ¼ 0.012), respectively (Figure 3a) . Adjusting for duration of antiretroviral therapy did not explain this association, as the adjusted regression coefficients still showed fat mass reductions of 1.6% (95% CI: 0.7-2.48; P ¼ 0.001) and 1.2% (95% CI: 0.2-2.2; P ¼ 0.017) per each 0.1 unit reduction in total lipin mRNA Log 10 in the femorogluteal and abdominal region, respectively. In contrast to the results for percentage limb fat, percentage truncal fat was negatively correlated with lipin levels in the adipose tissue of HIV patients (Figure 3b) . A univariate regression analysis revealed that a 0.1 unit reduction in total lipin mRNA Log 10 (normalized as lipin mRNA/18S rRNA) in the abdominal region resulted in an increase in percentage truncal fat of 1.4% (95% CI: 0.9-2.0; Po0.0001). This suggests distinct depot-specific relationships between lipin expression and fat mass, at least in the context of HIV-associated lipodystrophy.
Lipin levels are inversely correlated with adipocyte cytokine expression in HIV patients
Patients with HIV generally have low-grade inflammation associated with elevated circulating levels of cytokines, and increased cytokine expression in adipose tissue. [26] [27] [28] Furthermore, HIV patients with lipodystrophy, compared to those without lipodystrophy, typically have a higher degree of inflammation. Thus, patients with and without lipodystrophy represent a continuum of inflammatory response, but to date, there are no known inflammatory markers that distinguish patients with lipodystrophy from those without lipodystrophy. To assess whether a relationship exists between lipin expression and adipocyte production of inflammatory cytokines, we measured mRNA levels for TNFa, IL-6, IL-8 and IL-18 in abdominal subcutaneous fat. In general, these levels were higher in patients with lipodystrophy than in those without ( 
Discussion
Our findings reveal differences in lipin mRNA expression levels in the adipose tissue of HIV patients with and without lipodystrophy. We detected a positive correlation between lipin levels and percentage limb fat, and a negative correlation between lipin levels and inflammatory cytokine expression in adipose tissue. HIV patients without clinical lipodystrophy had higher lipin levels, maintained greater fat mass in the limbs and had lower cytokine expression levels in adipose tissue than their counterparts who had developed Analogous to lipin-deficient lipodystrophic mice, the adipose tissue of HIV patients with lipodystrophy showed significantly lower expression of total and individual lipin isoforms than patients without lipodystrophy. Furthermore, we found a tight association in HIV patients between lipin mRNA levels and percentage limb fat, which was not explained by duration of antiretroviral therapy. These results are consistent with the recently proposed role for lipin as an enzyme required for triacylglycerol synthesis. 20 In general, lipin mRNA levels were lower in the subcutaneous femorogluteal region compared with the subcutaneous abdominal region, perhaps reflecting the fact that lipoatrophy is most prominent in the adipose tissue of peripheral compartments. 5 In contrast to the positive correlation with subcutaneous fat, we found a negative correlation between lipin mRNA levels and percentage truncal fat. It must be acknowledged that the truncal fat measurements performed here by dual X-ray absorptiometry (DXA) cannot distinguish between visceral and subcutaneous fat depots, but DXA measurements of truncal fat have previously been validated to reflect visceral fat measured by computed tomography or magnetic resonance. [30] [31] [32] The negative relationship between lipin expression and truncal fat mass does not mirror results obtained in the mouse, where elevated lipin expression in adipose tissue leads to increased mass in visceral as well as subcutaneous depots. 18 This may indicate an atypical nature of the visceral fat, which typically increases in HIV/ antiretroviral-associated lipodystrophy. The current study also represents the first analysis of the lipin-a and -b isoforms in human adipose tissue depots. The finding of significantly lower lipin-a and -b levels in LD þ compared to LDÀ HIV patients is consistent with potential alterations in both adipocyte differentiation (lipin-a) and lipogenesis (lipin-b) in lipodystrophic adipocytes. 22 The observed elevation in lipin-b levels of LDÀ HIV patients compared to control subjects suggests that metabolic changes occur in the adipose tissue before the development of clinical lipodystrophy. The increased lipin expression in LDÀ patients was not associated with increased fat mass, as the LDÀ patients have a 25% reduction in fat mass compared to healthy controls. Nevertheless, as the LDÀ patients have substantially more fat mass than LD þ subjects, the increased lipin-b expression may lead to enhanced lipogenic gene expression and contribute to the maintenance of greater fat mass. It remains to be determined whether the elevated lipin expression observed in LDÀ patients reflects a subset of individuals with higher basal levels of lipin-b expression before treatment, or perhaps a compensatory increase in lipin expression in response to HIV infection or antiretroviral treatment. It also remains to be determined how lipin protein levels differ between LD þ and LDÀ subjects, as studies here examined mRNA levels. Adipose tissue may contribute to the inflammatory state observed in HIV infection through the production of cytokines, which may in turn contribute to the accelerated ischemic coronary artery disease observed in some HIV patients. 33 In line with previous reports, 34, 35 we found that cytokine expression in adipose tissue in general was higher in patients with HIV infection, and among these, patients with lipodystrophy had the highest expression. Furthermore, lipin expression levels were inversely correlated with adipose tissue inflammatory cytokine expression in HIV patients.
The current results do not allow us to distinguish whether low lipin levels contribute to the increased cytokine expression in the adipose tissue of LD þ patients or whether low lipin levels are a secondary consequence of this state. These findings are, however, consistent with observations in lipindeficient mice, which may have an increased inflammatory state leading to atherosclerosis despite an antiatherogenic lipid profile. 15 In the past few years, several mouse models with genetic modifications that reduce adipose tissue mass have been developed and found to display features of human lipodystrophies. 16, 36 These models provide useful tools to study the etiology and pathophysiology of lipodystrophy, and for the evaluation of potential therapeutic approaches.
Although no single mouse model may exactly recapitulate the human disease, the fld lipodystrophic mouse has been valuable in the identification of lipin as a new player in adipocyte differentiation and function. Given the central role of lipin in adipogenesis and lipogenesis and the present findings of distinct lipin expression levels in HIV patients with and without lipodystrophy, we suggest that variations in lipin expression may influence the pathogenesis of HIVassociated lipodystrophy.
